Disc Medicine (IRON) stock today: year-end rally keeps January FDA decision in focus
Disc Medicine, Inc. shares rose 3.3% to $79.41 in the last U.S. trading session of 2025, before Wall Street shut on Thursday for the New Year’s Day holiday.
Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next
Disc Medicine, Inc. stock is seeing a classic “biotech catalyst storm” on Dec. 20, 2025: big intraday swings, headline-driven volatility, and analysts arguing over whether the market is repricing risk or merely repricing uncertainty.
Disc Medicine (NASDAQ: IRON) Stock Tumbles on Insider-Selling Headlines as Bitopertin FDA Decision Nears — News, Analyst Forecasts, and What to Watch (Dec. 19, 2025)
Disc Medicine, Inc. stock sank sharply on Friday, Dec. 19, 2025, with IRON down about 10% in late-morning trading and swinging through a wide intraday range that, at one point, dipped into the low $70s before rebounding toward the low $80s. MarketScreener
Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets
Disc Medicine’s stock price spiked dramatically in mid-October 2025 after news of the FDA voucher, vaulting from the mid-$70s to the low-$90s in a single daygurufocus.com. On Friday, IRON opened around $85 and surged to an intraday high of $92.50 before closing at $93.00, marking a ~25% jump on the daystockanalysis.com. This leap capped a steady uptrend over the past month – the shares were trading near $60 in early September and gradually climbed into the $70s as anticipation built around bitopertin’s NDA filing and reviewstockanalysis.comstockanalysis.com. The FDA’s award of a priority review voucher was the clear catalyst for the latest rally, as it significantly accelerates Disc’s timeline to a potential approval. The stock’s year-to-date performance now far outpaces broader biotech indices, reflecting how quickly sentiment can turn when a small biotech achieves a major regulatory win.
TechStock² Updates
